Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

Serving two masters: US pharmaceutical marketing under FDA a...

Brett Heavner gives us the lowdown on the FDA regulations and the Lanham Act’s false advertising rules, both of which are vital when it comes to pharmaceutical marketing. Direct-to-consumer advertising has become a critical part of pharmaceutical marketing strategies since the...

Articles

Operational forecasting – making your numbers stand up

Forecasting plays a critical role across many aspects of marketing, so James MacDonald provides some pointers on the difference between a good and bad operational forecast. Operational forecasting quality can be quite variable across different operating companies, and improving this capability is one of the most rewarding activities in…

Articles

An outcomes focused NHS

Neil Cooper of Clinical Current explores the opportunities presented to pharma with the changing landscape of the NHS. The NHS in England is undergoing significant change and with it the way it defines success. The Health and Social Care Act 2012 set...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital